Are 2 combined antimicrobial mechanisms better than 1 for the treatment of acne vulgaris? Clinical and antimicrobial results of a topical combination product containing 1% clindamycin and 5% benzoyl peroxide. Introduction.
Acne vulgaris is the most common chronic skin condition seen by dermatologists. Available topical therapies include comedolytic agents such as tretinoin, adapalene, azelaic acid, tazarotene, and salicylic acid; bactericidal agents such as benzoyl peroxide; antibiotics such as clindamycin, erythromycin, and tetracycline; and anti-inflammatory agents such as sodium sulfacetamide and metronidazole. Therapeutic failure with some antibiotic regimens due to the presence or development of resistant strains is becoming an increasing problem in the treatment of acne. One strategy aimed at limiting the resistant Propionibacterium acnes population is the use of treatment regimens that incorporate agents with complementary but different mechanisms of action. A combination gel consisting of 5% benzoyl peroxide and 1% clindamycin has recently become available. This supplement summarizes the dermatopharmacology, clinical efficacy, and tolerability of this combination gel, along with its potential role in the management of acne vulgaris.
Leyden
J
J
Department of Dermatology, University of Pennsylvania Medical School, Philadelphia, USA.
D000152:Acne Vulgaris / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001585:Benzoyl Peroxide / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D006801:Humans
D000900:Anti-Bacterial Agents; D002981:Clindamycin; D001585:Benzoyl Peroxide